Medtech companies leveraging data must meet FDA and compliance-related requirements, especially given evolving laws and social concerns. Medtech partners Kristin Havranek, Martin Gomez, Matt Wetzel, Steven Tjoe discuss the top 5 compliance issues for medtech-enabled data platforms in MedCity News.
Related Content
- Life Sciences PerspectivesMay 31, 2024
Lawsuit Filed Challenging FDA Final Rule Regulating Laboratory Developed Tests
- AlertMay 31, 2024
Lawsuit Filed Challenging FDA Final Rule Regulating Laboratory Developed Tests
- Life Sciences PerspectivesMay 30, 2024
Designating a Platform Technology: FDA’s Long-Awaited Draft Guidance
- AlertMay 29, 2024
Designating a Platform Technology: FDA’s Long-Awaited Draft Guidance
- Life Sciences PerspectivesMay 22, 2024
The Appeals Review Panel’s In Re Xencor Decision: The USPTO Provides Its Position on Written Description and Means-Plus-Function Claims
- AlertMay 22, 2024
The Appeals Review Panel’s In Re Xencor Decision: The USPTO Provides Its Position on Written Description and Means-Plus-Function Claims
- Life Sciences PerspectivesMay 20, 2024
FDA Finalizes Rule and Sets Course to Phase In Oversight of Laboratory Developed Tests
- Big Molecule WatchMay 20, 2024
FDA Approves Boehringer Ingelheim’s CYLTEZO® Biosimilar to Humira for Multiple Chronic Inflammatory Diseases
- Press ReleaseMay 30, 2024
Novo Holdings and A.P. Moller Holding lead Funding Round in Circtec
- Press ReleaseMay 29, 2024
Akili Interactive to Be Acquired by Virtual Therapeutics
- Awards and RankingsMay 28, 2024
Goodwin Highly Ranked for the Q1 2024 League Tables for M&A, Private Equity, and Venture Capital
- Press ReleaseMay 24, 2024
Aktis Oncology and Eli Lilly Collaborate on Discovery and Development of Novel Anticancer Radiopharmaceuticals; Aktis To Receive $60 Million Upfront and up to an Additional $1.1 Billion in Potential Milestones
- Press ReleaseMay 22, 2024
Repertoire® Immune Medicines Collaborates with Bristol Myers Squibb to Develop Tolerizing Vaccines for Autoimmune Diseases, Upfront Payment of $65 Million with up to $1.8 Billion in Milestones and Potential Tiered Royalties
- Press ReleaseMay 22, 2024
Human Immunology Biosciences to be Acquired by Biogen For $1.15 Billion Upfront and up to $650 Million in Potential Milestone Payments
- Press ReleaseMay 21, 2024
Pheon Therapeutics Completes $120 million Series B
- Press ReleaseMay 20, 2024
Technology Partner Andrew Harper Joins Goodwin in Silicon Valley